-
平臺(tái)編號(hào)：bio-129603
-
細(xì)胞信息： HCC515
-
規(guī)格：1×10?cells/T25培養(yǎng)瓶
-
用途：STR
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
人肺腺癌細(xì)胞HCC515
細(xì)胞名稱：人肺腺癌細(xì)胞HCC515
產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細(xì)胞數(shù)量：1x10^6；1x10^6
保存溫度：37℃；-198℃
運(yùn)輸方式：常溫保溫運(yùn)輸；干冰運(yùn)輸
安全等級(jí)：1
用途限制：僅供科研4類
培養(yǎng)體系：DMEM高糖（不含丙酮酸鈉）+10%FBS+1%三抗
培養(yǎng)溫度：37℃
二氧化碳濃度：5%
簡(jiǎn)介：人肺腺癌細(xì)胞HCC515取自39歲女性供體，貼壁培養(yǎng)。
注釋
Part of:Cancer Cell Line Encyclopedia(CCLE)project.
Part of:MD Anderson Cell Lines Project.
Doubling time:39.3 hours(PubMed=29681454).
Omics:Deep exome analysis.
Omics:Deep RNAseq analysis.
Omics:Protein expression by reverse-phase protein arrays.
Omics:SNP array analysis.
Omics:Transcriptome analysis.
突變信息
Homozygous for CDKN2A p.Asp84His(c.250G>C)(CCLE).
Heterozygous for KRAS p.Gly13Asp(c.38G>A)(ClinVar=VCV000012580)(CCLE).
Homozygous for TP53 p.Leu194Phe(c.580C>T)(ClinVar=VCV000127817)(CCLE).
STR信息
Amelogenin X
CSF1PO 10
D3S1358 15,16
D5S818 11
D7S820 7,8
D8S1179 14,15
D13S317 8
D16S539 11,13
D18S51 9,20
D21S11 29,30
FGA 20,22
Penta D 11,15
Penta E 9,16
TH01 7
TPOX 8,11
vWA 15,17
參考文獻(xiàn)
PubMed=29681454;DOI=10.1016/j.cell.2018.03.028
McMillan E.A.,Ryu M.-J.,Diep C.H.,Mendiratta S.,Clemenceau J.R.,Vaden R.M.,Kim J.-H.,Motoyaji T.,Covington K.R.,Peyton M.,Huffman K.,Wu X.-F.,Girard L.,Sung Y.,Chen P.-H.,Mallipeddi P.L.,Lee J.Y.,Hanson J.,Voruganti S.,Yu Y.,Park S.,Sudderth J.,DeSevo C.,Muzny D.M.,Doddapaneni H.,Gazdar A.F.,Gibbs R.A.,Hwang T.-H.,Heymach J.V.,Wistuba I.,Coombes K.R.,Williams N.S.,Wheeler D.A.,MacMillan J.B.,Deberardinis R.J.,Roth M.G.,Posner B.A.,Minna J.D.,Kim H.S.,White M.A.
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Cell 173:864-878.e29(2018)
PubMed=31068700;DOI=10.1038/s41586-019-1186-3
Ghandi M.,Huang F.W.,Jane-Valbuena J.,Kryukov G.V.,Lo C.C.,McDonald E.R.III,Barretina J.,Gelfand E.T.,Bielski C.M.,Li H.,Hu K.,Andreev-Drakhlin A.Y.,Kim J.,Hess J.M.,Haas B.J.,Aguet F.,Weir B.A.,Rothberg M.V.,Paolella B.R.,Lawrence M.S.,Akbani R.,Lu Y.,Tiv H.L.,Gokhale P.C.,de Weck A.,Mansour A.A.,Oh C.,Shih J.,Hadi K.,Rosen Y.,Bistline J.,Venkatesan K.,Reddy A.,Sonkin D.,Liu M.,Lehar J.,Korn J.M.,Porter D.A.,Jones M.D.,Golji J.,Caponigro G.,Taylor J.E.,Dunning C.M.,Creech A.L.,Warren A.C.,McFarland J.M.,Zamanighomi M.,Kauffmann A.,Stransky N.,Imielinski M.,Maruvka Y.E.,Cherniack A.D.,Tsherniak A.,Vazquez F.,Jaffe J.D.,Lane A.A.,Weinstock D.M.,Johannessen C.M.,Morrissey M.P.,Stegmeier F.,Schlegel R.,Hahn W.C.,Getz G.,Mills G.B.,Boehm J.S.,Golub T.R.,Garraway L.A.,Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)
PubMed=31803961;DOI=10.1002/jcb.29564
Mulshine J.L.,Ujhazy P.,Antman M.,Burgess C.M.,Kuzmin I.,Bunn P.A.Jr.,Johnson B.E.,Roth J.A.,Pass H.I.,Ross S.M.,Aldige C.R.,Wistuba I.I.,Minna J.D.
From clinical specimens to human cancer preclinical models--a journey the NCI-cell line database-25 years later.
J.Cell.Biochem.121:3986-3999(2020)
細(xì)胞操作說(shuō)明書(shū)下載：細(xì)胞操作說(shuō)明書(shū)
產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細(xì)胞數(shù)量：1x10^6；1x10^6
保存溫度：37℃；-198℃
運(yùn)輸方式：常溫保溫運(yùn)輸；干冰運(yùn)輸
安全等級(jí)：1
用途限制：僅供科研4類
培養(yǎng)體系：DMEM高糖（不含丙酮酸鈉）+10%FBS+1%三抗
培養(yǎng)溫度：37℃
二氧化碳濃度：5%
簡(jiǎn)介：人肺腺癌細(xì)胞HCC515取自39歲女性供體，貼壁培養(yǎng)。
注釋
Part of:Cancer Cell Line Encyclopedia(CCLE)project.
Part of:MD Anderson Cell Lines Project.
Doubling time:39.3 hours(PubMed=29681454).
Omics:Deep exome analysis.
Omics:Deep RNAseq analysis.
Omics:Protein expression by reverse-phase protein arrays.
Omics:SNP array analysis.
Omics:Transcriptome analysis.
突變信息
Homozygous for CDKN2A p.Asp84His(c.250G>C)(CCLE).
Heterozygous for KRAS p.Gly13Asp(c.38G>A)(ClinVar=VCV000012580)(CCLE).
Homozygous for TP53 p.Leu194Phe(c.580C>T)(ClinVar=VCV000127817)(CCLE).
STR信息
Amelogenin X
CSF1PO 10
D3S1358 15,16
D5S818 11
D7S820 7,8
D8S1179 14,15
D13S317 8
D16S539 11,13
D18S51 9,20
D21S11 29,30
FGA 20,22
Penta D 11,15
Penta E 9,16
TH01 7
TPOX 8,11
vWA 15,17
參考文獻(xiàn)
PubMed=29681454;DOI=10.1016/j.cell.2018.03.028
McMillan E.A.,Ryu M.-J.,Diep C.H.,Mendiratta S.,Clemenceau J.R.,Vaden R.M.,Kim J.-H.,Motoyaji T.,Covington K.R.,Peyton M.,Huffman K.,Wu X.-F.,Girard L.,Sung Y.,Chen P.-H.,Mallipeddi P.L.,Lee J.Y.,Hanson J.,Voruganti S.,Yu Y.,Park S.,Sudderth J.,DeSevo C.,Muzny D.M.,Doddapaneni H.,Gazdar A.F.,Gibbs R.A.,Hwang T.-H.,Heymach J.V.,Wistuba I.,Coombes K.R.,Williams N.S.,Wheeler D.A.,MacMillan J.B.,Deberardinis R.J.,Roth M.G.,Posner B.A.,Minna J.D.,Kim H.S.,White M.A.
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Cell 173:864-878.e29(2018)
PubMed=31068700;DOI=10.1038/s41586-019-1186-3
Ghandi M.,Huang F.W.,Jane-Valbuena J.,Kryukov G.V.,Lo C.C.,McDonald E.R.III,Barretina J.,Gelfand E.T.,Bielski C.M.,Li H.,Hu K.,Andreev-Drakhlin A.Y.,Kim J.,Hess J.M.,Haas B.J.,Aguet F.,Weir B.A.,Rothberg M.V.,Paolella B.R.,Lawrence M.S.,Akbani R.,Lu Y.,Tiv H.L.,Gokhale P.C.,de Weck A.,Mansour A.A.,Oh C.,Shih J.,Hadi K.,Rosen Y.,Bistline J.,Venkatesan K.,Reddy A.,Sonkin D.,Liu M.,Lehar J.,Korn J.M.,Porter D.A.,Jones M.D.,Golji J.,Caponigro G.,Taylor J.E.,Dunning C.M.,Creech A.L.,Warren A.C.,McFarland J.M.,Zamanighomi M.,Kauffmann A.,Stransky N.,Imielinski M.,Maruvka Y.E.,Cherniack A.D.,Tsherniak A.,Vazquez F.,Jaffe J.D.,Lane A.A.,Weinstock D.M.,Johannessen C.M.,Morrissey M.P.,Stegmeier F.,Schlegel R.,Hahn W.C.,Getz G.,Mills G.B.,Boehm J.S.,Golub T.R.,Garraway L.A.,Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)
PubMed=31803961;DOI=10.1002/jcb.29564
Mulshine J.L.,Ujhazy P.,Antman M.,Burgess C.M.,Kuzmin I.,Bunn P.A.Jr.,Johnson B.E.,Roth J.A.,Pass H.I.,Ross S.M.,Aldige C.R.,Wistuba I.I.,Minna J.D.
From clinical specimens to human cancer preclinical models--a journey the NCI-cell line database-25 years later.
J.Cell.Biochem.121:3986-3999(2020)
細(xì)胞操作說(shuō)明書(shū)下載：細(xì)胞操作說(shuō)明書(shū)
